Jiangsu Hengrui Pharmaceuticals (01276): HRS-1597 tablets have obtained the Drug Clinical Trial Approval Notice.
Hengrui Medicine (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for HRS-1597 tablets, and will soon initiate clinical trials.
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Clinical Trial Approval Notice for HRS-1597 tablets issued by the National Medical Products Administration (NMPA), and will soon commence clinical trials.
Related Articles
SCIENTECH (02291) spent HKD 2.2152 million on September 7 to buy back 175,000 shares.
Windey Energy Technology Group (300772.SZ) plans to transfer its 100% equity in Zhangbei Qida New Energy.
SF INTRA-CITY (09699) spent HKD 832,000 to repurchase 97,000 shares on September 7.
SCIENTECH (02291) spent HKD 2.2152 million on September 7 to buy back 175,000 shares.
Windey Energy Technology Group (300772.SZ) plans to transfer its 100% equity in Zhangbei Qida New Energy.
SF INTRA-CITY (09699) spent HKD 832,000 to repurchase 97,000 shares on September 7.
RECOMMEND
